Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAPOX + FOLFOX
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
CAPOX + FOLFOX refers to two distinct chemotherapy regimens used primarily for colorectal cancer treatment. CAPOX combines capecitabine (oral) and oxaliplatin (IV), while FOLFOX combines folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin. Both regimens target rapidly dividing cancer cells but through slightly different administration methods. FOLFOX is administered entirely intravenously in a clinical setting, while CAPOX allows patients to take capecitabine tablets at home with only oxaliplatin administered in the hospital.
- Brand names
- Eloxatin (oxaliplatin)Xeloda (capecitabine)
- Other names
- XELOX + FOLFOXOxaliplatin de Gramont + CAPOXOxMdG + CAPOX
02
Targets
TS (Thymidylate synthase)
Beyond the preview
Go deeper on CAPOX + FOLFOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAPOX + FOLFOX.